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Abstract 
A population-based study of the sera-
epidemiology of chlamydia was performed 
among a nationally representative sample of 
760 Costa Rican women aged 25 to 59 years. 
Interviews and sera collection were completed 
between September 1984 and February 1985. 
The overall seroprevalence of chlamydial 
antibodies among these women was 56-1%. 
Women 25 to 39 years of age had a sero-
prevalence of 511%, while women 40 to 59 
years of age had a seroprevalence of 64-2%. 
Women who reported no prior sexual activity 
had a seroprevalence rate of 48.6%, compared 
with a seroprevalence rate of 80.7% among 
women who reported three or more lifetime 
sexual partners. The geometric mean titre 
(GMT) of seropositive women ranged from 
34.4 among the women who reported no prior 
sexual activity to 155.0 among the women with 
three or more lifetime sexual partners. Seer,-
positivity was more consistently associated 
with sexual activity than with age. Women with 
serological evidence of past Herpes simplex 
virus type 2 (HSV-2) or syphilis infection were 
more likely to be seropositive than were 
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women without evidence of exposure to these 
sexually transmitted diseases, even when con-
trolled for age and the number of lifetime 
sexual partners. 
The seropositivity among never sexually 
active women indicates the probable presence 
of Chlarnydia pneurnoniae infections, while 
the high seroprevalence of chlamydial anti-
bodies among the sexually active women sug-
gests that sexually transmitted Chlamydicr 
grachomaxis infections represent a public 
health problem not previously quantified in 
Costa Rica. Further seroepidemiological and/ 
or culture studies are warranted to determine 
the incidence and prevalence of sexually trans-
mitted chlamydial infection among men am 
younger women. 
In developed countries, Chlamydia rrachomaris has 
become a focus of public health concern because C 
rrachomaris infections occur more frequently than 
any other sexually transmitted disease (STD). 
Chlarnydial infection rates in the United States and 
Great Britain appear to have increased over the last 
decade.' Acute salpingitis in females caused by C 
trachomatis may lead to infertility and/or ectopic 
pregnancy. C read:cm:ads can also cause inclusio-
conjunctivitis and pneumonia of the newbor. 
through perinatal transmission of the infection. Only 
limited information on the prevalence and trends of 
chlarnydial STDs in developing countries is 
available. 
Few population-based or population-represen-
tative studies examining the seroprevalence of 
chlamydial antibodies have been published. 
Population-based serological studies with detailed 
demographic information, and data on reproductive 
health and sexual habits are not available. We report 
here a study of the seroprevalence of chlamydiz: 
antibodies in Costa Rican women 25 to 59 years c: 
age. 
Methods 
POPULATION 
We studied a nationally repre,.entative sample of 
Costa Rican women 25 to 59 years of age who were 
previously enrolled as controls in a case-control 
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study of contraceptive use and the risk of cervical and 
breast cancer in Costa Rica." These _women were 
selected through a household survey using a multi-
stage, probability sample design, with a sampling 
frame based on the 1984 Costa Rican census. The 
sampling frame excluded sparsely populated regions 
representing 5°° of the population. Some five-year 
age groups were oversarnpled for the methodologic 
design of the cancer study. 
INTERVIEWS AND SERUM COLLECTION 
The survey obtained medical, reproductive, and 
sexual histories using a modified version of the 
tdardised questionnaire from the US Centers for 
idiSease Control's Cancer and Steroid Hormone 
Study.' Trained female interviewers administered 
the questionnaire between September 1984 and 
February 1985. Shortly after the interview, a 
laboratory technician collected blood specimens 
from consenting interviewees. 
LABORATORY DETERMINATIONS 
We determined IgG titres of anti-chlamydial 
antibody using the simplified microimmunofluores-
cence (MIF) technique! We considered a titre 
greater than or equal to 1:16 positive for chlamydial 
antibody. The sera were also tested for antibodies to 
syphilis and Herpes simplex type 2 (HSV-2), using 
the microhemagglutination assay for Treponema 
pallidum (IviHA-TP)1 and a type-specific 
glycoprotein antigen test,' respectively. 
ANALYSIS 
We analysed seroprevalence by: age; number of 
lifetime sexual partners; serological evidence of prior 
or syphilis infection; history of infertility—a 
s;_.--report of any unsuccessful attempt to become 
pregnant for 24 consecutive months; history of pelvic 
inflammatory disease (PID)—a self-report of a doc-
tor's diagnosis of infection of the uterus or tubes or 
inflammation of the pelvis; region of residence; and 
education as an indicator of socioeconomic status.  
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In calculating seroprevalence we used a weighting 
scheme based on the inverse of the sampling fraction 
to compensate for the oversarnpling of some 5 year 
age intervals. The standard errors used to calculate 
confidence limits were estimated using a Taylor 
series linearisation, as performed by SESUDAAN, a 
SAS procedure," which accounts for both age-
weighting and the cluster sample design. 
To control for the possible effect of age and the 
number of lifetime sexual partners on the 
seroprevalence rates by other characteristics, we 
stratified the results into two age groups (25 to 39 and 
40 to 59 years) and two groups based on the number 
of lifetime sexual partners (less than two and two or 
more). 'We calculated the geometric mean titre 
(GMT) of chlamydial antibody of seropositive 
women using unweighted data. 
Results 
Of the 935 women eligible for the study, 870 (93.0%) 
consented to an interview and 767 of those inter-
viewed permitted the technician to draw a blood 
sample. Women for whom no serum was available 
were similar to those with a serum specimen with 
regard to age, parity, region of residence, education, 
and economic status." We obtained valid chlamydial 
antibody titre results for 760 women. These 760 
women (87-4°0 of those interviewed) constitute our 
nationally representative study population. 
The overall weighted seroprevalence of chlamydial 
antibody was 56- 1°0 (table 1). Titres ranged from 0 
to 1:4,096. Among women less than 40 years of age 
seroprevalence was 51.1 0 0 , while for women 40 years 
of age and over seroprevalence was 64.2% (table 2). 
Seroprevalence increased with increasing age up to 
49 years (table 1). When we controlled for sexual 
activity, in each age group women with two or more 
lifetime sexual partners had higher seropositivity 
rates than women with less than two lifetime sexual 
partners. However, the stratification did not change 
the general pattern in seroprevalence by age. Among 
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Table 2 Chlanrydial antibody status: Percent stropositive• and geometric mean titre (GMT) by number of lifetime sexual partners b:. qe 
among Costa Rican women, 25-59 years of age, 1984-85 
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all seropositive women and seropositive women with 
less than two lifetime sexual partners those 30 to 39 
years old had the highest GMT; however, among 
seropositive women with two or more lifetime sexual 
partners those 25 to 29 years old had the highest 
GMT (table 1). 
Chlai-nydial seropositivity increased from 48.6% 
for women reporting no previous sexual experience 
to 80.7% for those with three or more lifetime sexual 
partners (table 2). Stratification of the women into 
two age groups resulted in lower seropositivity rates 
for women less than 40 years of age at each sexual 
partner level. However, the pattern of increasing 
seropositivity with increasing number of lifetime 
sexual partners remained when the small group of 
older, never sexually active women was excluded 
(table 2). The GMT of seropositive women increased 
from 34-4 for women who reported no coitus to 155.0 
for women with three or more lifetime sexual part-
ners (table 2). When we controlled for age, within 
each sexual partner group, women 40 years and over 
had lower GMTs than women less than 40 years of 
age, except the small group of women who were never 
sexually active. However, the pattern of increasing  
GMT with an increasing number of lifetime sexual 
partners did not change (table 2). 
Serological evidence of prior HSV-2 or syphilis 
infection were associated with similar increases in 
chlamydial seropositiviry (table 3) even when we 
controlled for age and the number of lifetime sexual 
partners. 
Women who reported a history of prior PID did 
not have higher seropositivity rates than women who 
denied a history; however, the GMT of seropositive 
women who reported a history of PID was 1102 
whereas for seropositive women who denied a history 
of PID the GMT was 79.6 (table 4). The GMT of 
scropositive women who reported a history of infer-
tility was 96•3 while for seropositive women who 
denied a history of infertility the GMT was 82.0. A 
history of infertility was associated with increased 
chlamydial seroprevalence only in women 40 years of 
age and over, and women with two or more lifetime 
sexual partners (data not shown). 
Seropositivity varied with educational level. 
Although the pattern of seropositivity varied slightly 
with age and the number of lifetime sexual partners, 
women with a university education generally had the 
lowest rates c 
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Table 3 Chlarrtydial antibody status: Percent seropositive* by syphilis and herpes simplex virus type-2 (HS V-2 ) antibody status by 
age and by number of lifetime sexual partners among Costa Rican women, 25-59 years of age, 1984-8.5 
Age (yr ) 
All women 	 25-39 	 59 
95% 	 95% Confidence 	 Percent 	 Confidence 
interval 	 positive 	 (N) 	 interval 
Syphilis 
Negative 
Positive 
54.5 
79.2 
(706) 
(54) 
(50.1-5883 
166-2-92 31 
502 
68 0 
(369) 
(19) 144•0-56 43 (45-3-90.81 
HSV-2: 
Negative 45-8 (441) [40-3-51 3( 40 8 (sot) 133.4-48 2 
Positive 71-3 (312) (65.6-77-0) 69 0 (144) 160-5-7751 
'Percent seropositive is age weighted. 
tTwo women with an unknown number of lifetime sexual partners were excluded from the analysis. 
:Seven women with an unknown HSV-2 serology result were excluded from the analysis. 
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All women 
95!: GMT 
Percent Confidence positive 
History of pa:um( Ni( Uurmed titres 
Infertility 
Yes 63.4 (59)(491-77.71 96-3 
No 55.5 (701) 151 2-59.71 8243 
PIDt 
Yes 53.4 (95) 143.4-6161 110 2 
No 56.6 (661) 152.1-61-01 79.6 
•Percent seroposinve is age weighted, 
tFour women with an unknown history of P1D were excluded 
from the analysis. 
lowest rates of seropositivity, whereas women with 
no formal education generally had the highest 
seropositivity rates (table 5). 
We found differences in seropositiviry rates by 
region of residence, which remained when we con-
trolled for age and the number of lifetime sexual 
partners of the women. Among all women, those 
from San Jose and the urban areas outside of the 
central valley (principally the port cities of Liman 
and Puntarenas) had the highest seroprevalence rates 
(59.9% and 68.6% respectively). When we stratified 
by age and by number of sexual partners, the highest 
seroprevalence was always among women from one 
of these two regions (data not shown). 
Discussion 
We found a high seroprevalence of chlamydial 
antibody among Costa Rican women (56.1°0. This 
seroprevalence rate is in the mid-range of 
seroprevalence rates (12%-91%) of other studies of 
selected female populations in developing coun-
tries.'" In developed countries, chIamydial 
seroprevalence studies have found seroprevalence 
rates of 17°,0-27%.'" 
Antibody to chlamydia may be acquired from 
sexually transmitted C trachomans infections, 
trachoma, ornithosis, and respiratory infections from 
C pnewnoniae (strain TWAR),""" or, perhaps, from 
perinatally acquired C tsar-km=6s infections. Tra-
choma is not recognised as a public health problem in 
Costa Rim. Data from other studies suggest that the 
persistence of perinatally acquired antibodies would 
not contribute significantly to seropositivity in the 
age groups sr.died.'" Prior infection by C psittaci 
might be resp nsible for some of the antibody in this 
study; howev r, it is unlikely that exposure to avian 
strains of C ; sirtaci is responsible for much of the 
seroprevaleni 2 as clinical omithosis has not been 
recognised in large proportions of the population in 
Costa Rica. 
C pneurnor, jar infections are probably responsible 
for some of the seropositiviry in our study. Although 
the degree tf cross-reactivity to C trachornads as 
measured by our MIF is uncertain, we suspect that a 
considerable amount of the antibody detected is a 
result of C pnewnoniae infections." No studies of C 
pncurnaniae in Costa Rica are known to the authors. 
In the United States and Denmark, antibody 
prevalence to Cpneurnortirte increases with age, with 
up to 400 0 
 of adults seropositive." In this study, a 
high proportion (48.6%) of the 36 women reporting 
no coitus had positive chlamydial antibody titres. 
San Joaquin et al 15 reported a 43,2% seropositiviry 
rate among 9 to 11 year olds in Oklahoma, and Black 
et a! reported a 33-3% seropositivity rate for girls of 
the same age in San Francisco. In a study of female 
college students 23c,'0 of those who reported no prior 
sexual experience were found to be seropositive." Of 
interest, the GMT of nonsexually active seropositive 
women in our study (34.4) was considerably lower 
than that of the sexually active seropositive popula-
tion, which ranged from 67.6 to 155.0 (table 2). 
Seropositivity in women reporting no sexual 
activity may reflect misclassification of the women 
due to inaccurate information regarding previous 
Table 4 Chlamydial antibody status: Percent seropositive* 
and GMT by history of infertility and PIA among Costa 
- 	 Rican women, 25-59 years of age, 198445 
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Table 5 Chlarrrydial antibody status; Percuu seropositive* by educeuional level by age and by number of lifetime sexual pant.. rs 
among Costa Rican women, 25-59 years of age, 1984-85 
Ale (Yr) 
Ali women 
	 25-39 
Educational 
level 
Percent 
positive (N) 
95% 
Giserfulenes 
asteroid 
Percent 
paninte ( N ) 
95% 
Confidence 
interval (N) 
None 
Primary Incomplete 
Primary Complete 
Secondary 
University 
65.0 
583 
54.2 
56-3 
45-7 
(79) (257) 
(185) 
(170) 
(69) 
1534-76.61 
152-0-64•91 
46-1-62.31 
48.9-63-8,1 
33-6-57.71 
66.5 
51-1 
488 
56.0 
35.3 
(23) 
(89) 
(111) 
(122) 
(43) 
46.4-86-61 
39.9-62-31 
38.6-59-0) 
47.6-64-5! 
19-7-50-9, 
(56) 
(168) 
(74) 
(48) 
(26) 
 
"Percent seropositive is age weighted. 
?Two women with an unknown number of lifetime sexual partners were excluded from the analysis. 
sexual experience. In a separate analysis of our study 
population, 6.4% of all women were found to be 
reactive for T pallidum by MHA-TP; however, none 
of the women who reported no coitus were reactive 
(Larsen SA, unpublished data). Exposure to C 
pneumoniae may explain a large proportion of the 
sexually inexperienced women found to have 
chlamvdial antibody in this study. 
Despite the evidence for nonsexually transmitted 
chlamydial infections in our study population, there 
is also considerable evidence of sexually transmitted 
chlamydia. The number of lifetime sexual partners 
was the characteristic most consistently associated 
with high seroprevalence. As the number of lifetime 
sexual partners increased, seroprevalence increased, 
a pattern found with most STDs. The GMT also 
increased as the number of lifetime sexual partners 
increased. This could reflect the greater risk of 
complicated and/or multiple infections with 
additional partners, as complicated infections and 
multiple episodes usually result in higher persistent 
antibody concentrations than do uncomplicated 
infections or a single episode." 
In addition to the dose-response pattern of 
increasing antibody prevalence and levels with an 
increasing number of lifetime sexual partners, we 
found that HSV-2 and syphilis seropositivity were 
associated with about a one third increase in 
chlamydial seropositivity. We would expect women 
with evidence of one STD to be more likely to show 
evidence of another STD. 
There was no consistent association of chlamydial 
antibody with a history of PID or infertility. The 
GMT of seropositive women who reported PID was 
greater than the GMT of those seropositive women 
who denied a history of PID; however, there was no 
increase in chlamydial seropositiviry for those 
women who reported a history of PID compared with 
those who did not. The lack of correlation between 
positive titres and a history of PID may be a result of 
inaccurate reporting of PID due to misunderstand-
ing of the term, the subclinical nature of much 
chlamydial PID, or the presence of chlamydial  
antibodies not acquired from sexually transmitted 
infections. The reported history of PID in this study 
population (12.8%) is similar to that reported in the 
United States.' 
The lack of definitive information on the natural 
history of chlamydial antibody as well as the cross-
sectional nature of this study limit speculation 
regarding the reasons for variation in seroprevalence 
by age. The differences in seroprevalence anc 
antibody levels by age could represent the influence 
of: (1) the incidence of infection among cohorts of 
women, (2) the varying risk of exposure to 
chlamydial infection with age, (3) the differing rates 
of infection which result in high antibody titres (such 
as salpingitis), and/or (4) the changes in antibody 
levels for individual women over time. 
Longitudinal studies could better define the varia-
tion of chlamydial antibody with age. Additional 
cross-sectional studies could provide valuable infor-
mation for interpretation of results if their designs 
included men and women less than 25 years of age i 
the study population, as well as additional inform: 
tion on the sexual habits of the study participant 
and their partners. 
Our results suggest that in Costa Rica, Cpneumon-
iae infections are probably common and that C 
trachomatis is an important agent of sexually trans-
mitted infections. In a study of two Costa Rican clinic 
populations, the prevalence of culture-confirmed 
genital chlamydial infections was low: 2.9% in men 
visiting an STD clinic and 0-58% among women 
visiting a family planning clinic for non-STD 
reasons." The relatively low prevalence may be du 
to the inherent difficulties of chlamydial culture. 
recent case-control study in Costa Rica found that C 
traciumtatis was responsible for 33% of hospitalised 
cases of infant pneumonia.' 
The information provided by this and the other 
Costa Rican chlamydia studies indicates the need to 
gather further data to enable future development of 
a chlamydial control program. Population-based 
studies of C trachomacis genital infections could 
provide estimates of current rates of sexually trans- 
mitted chlar 
plan prevent 
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